Navigation Links
Senators Lautenberg and Menendez Vote to Protect America's Kids from Tobacco
Date:6/11/2009

WASHINGTON, June 11 /PRNewswire-USNewswire/ -- The Campaign for Tobacco-Free Kids applauds U.S. Senators Frank Lautenberg and Robert Menendez for voting today to approve historic legislation that gives the U.S. Food and Drug Administration (FDA) authority to regulate tobacco products, including the authority to crack down on tobacco marketing and sales to kids. The U.S. Senate approved the bipartisan bill 79 to 17. The House has approved similar legislation, and Congress is expected to quickly send a final bill to President Obama, who is eager to sign it into law. Both senators were co-sponsors of the bill.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )

"Senators Lautenberg and Menendez have been leaders in this historic effort to protect our children from tobacco addiction and save lives," said Matthew L. Myers, President of the Campaign for Tobacco-Free Kids. "This legislation represents the strongest action Congress has ever taken to reduce tobacco use, the number one cause of preventable death in the United States. If effectively implemented, this legislation will significantly reduce the number of children who start to use tobacco, the number of adults who continue to use tobacco and the number of people who suffer and die as a result."

FDA regulation of tobacco products is an essential step toward improving health and reducing health care costs in the United States. Tobacco use kills more than 400,000 Americans and costs the nation $96 billion in health care bills each year. Every day, more than 3,500 U.S. kids try their first cigarette. Yet tobacco products have been exempt from the FDA's common-sense regulations that apply to virtually every other product we consume, from food to drugs to cosmetics.'/>"/>

SOURCE Campaign for Tobacco-Free Kids
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Senators Specter and Casey Vote to Protect Americas Kids from Tobacco
2. Senators Mikulski and Cardin Vote to Protect Americas Kids From Tobacco
3. Senators Kohl and Feingold Vote to Protect Americas Kids From Tobacco
4. Senators Feinstein and Boxer Vote to Protect Americas Kids from Tobacco
5. Senators Murkowski and Begich Vote to Protect Americas Kids from Tobacco
6. Senators Baucus and Tester Vote to Protect Americas Kids From Tobacco
7. Senators Lincoln and Pryor Vote to Protect Americas Kids From Tobacco
8. Senators Levin and Stabenow Vote to Protect Americas Kids from Tobacco
9. Senators Snowe and Collins Vote to Protect Americas Kids from Tobacco
10. Randall Terry: How Tillers Death and office Closing Can Help Propel Pro-Life Movement, Derail Sotomayor and Overturn Roe; Four Key Senators Will Be Targeted to Vote Against Sotomayor; Catholic Bishops Will Play a Role to Defeat Sotomayor
11. Senators Who Signed Letter Opposing Public Health Plan Took $17.7 Million in Campaign Donations from Health Care and Insurance Industries
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6New Robotic Arm Has Softer Surgical Touch 55753 1New Robotic Arm Has Softer Surgical Touch 55753 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 1Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 3Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 1Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 2Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 3
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2